AM33249PU-N IPO-38 Proliferation marker antibody

See related secondary antibodies

Search for all "IPO-38 Proliferation marker"

0.2 mg / €390.00
Please visit the country specific website of Acris Antibodies or contact your local Distributor to buy this product.

Quick Overview

Mouse anti Human, Mouse, Rat IPO-38 Proliferation marker SPM260

Product Description for IPO-38 Proliferation marker

Mouse anti Human, Mouse, Rat IPO-38 Proliferation marker SPM260.
Presentation: Purified
Product is tested for Flow Cytometry, Immunocytochemistry/Immunofluorescence, Paraffin Sections.

Properties for IPO-38 Proliferation marker

Product Category Primary Antibodies
Quantity 0.2 mg
Synonyms IPO38
Presentation Purified
Reactivity Hu, Ms, Rt
Applications F, ICC/IF, P
Clonality Monoclonal
Clone SPM260
Host Mouse
Isotype IgM
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer Acris Antibodies GmbH
Material safety datasheet MSDS for Monoclonal Antibodies (de)

Datasheet Extract

Immunogen
Immunogen:
Spleen cells of a patient with hairy cell leukemia.
Application Flow Cytometry: 0.5-1 µg/106 cells.
Immunofluorescence:
0.5-1 µg/ml. 
Immunohistochemistry on Formalin-Fixed 
Paraffin Sections: 0.5-1 µg/ml for 30 minutes at RT. 
Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes. 
Positive Control: Raji and PHA-stimulated (>12 hours) human or mouse lymphocytes. Breast and colorectal carcinomas.
Background IPO-38 antigen is present in the nuclei of proliferating cells such as Hodgkin’s disease and non-Hodgkin’s lymphomas, different forms of leukemias, breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the cells of non-stimulated lymphocytes and granulocytes. IPO-38 can be a useful marker of cell proliferation during monitoring of tumor progression.
Concentration 0.2 mg/ml
General Readings
  1. Sidorenko SP, Vetrova EP, Iurchenko OV, Shlapatskaia LN, Berdova AG, Elenskaia AM, et al. [Monoclonal antibodies of the IPO series in studying and diagnosing malignant lymphoproliferative diseases]. Gematol Transfuziol. 1990 Apr;35(4):19-22. PubMed PMID: 2373343.
  2. Mikhalap SV et al. Monoclonal antibody IPO-38 recognizes a novel nuclear antigen of proliferating cells. In Kishimoto T et al eds. Leukocyte Typing VI, p609-610, Garland Publishing, New York, 1997.
  3. Mathews MB, Bernstein RM, Franza BR, Garrels JI. Identity of the proliferating cell nuclear antigen and cyclin. Nature. 1984 May 24-30;309(5966):374-6. PubMed PMID: 6145097.
Storage Store undiluted at 2-8°C.
DO NOT FREEZE!
Shelf life: one year from despatch.
Format
Buffer System:
10mM PBS
Preservatives:
0.05% Sodium Azide
Stabilizers:
0.05% BSA
State:
Liquid purified IgG fraction from Bioreactor Concentrate
Purified
Species Reactivity
Species reactivity (tested):
Human, Mouse, Rat.
Specificity
Specificity:
Recognizes a protein of 14-16kDa, which is a novel nuclear antigen of proliferating cells. IPO-38 antigen is present in the nuclei of proliferating cells such as Hodgkin’s disease and non-Hodgkin’s lymphomas, different forms of leukemias,  breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the cells of non-stimulated lymphocytes and granulocytes.
IPO-38 can be a  useful marker of cell proliferation during monitoring  of tumor progression.
Cellular Localization: Nuclear.

Accessory Products

  • LinkedIn